The effects of thyroid-stimulating antibodies (TSAb) and of thyrotropin (TSH) were compared, on the generation of cyclic AMP and inositol phosphates (InsP), in human thyroid slices incubated in vitro, and on the Rapoport cyclic AMP bioassay. The TSAb positive sera were obtained from 19 patients with Graves' disease. In 14 experiments with the slices system, TSH significantly increased cyclic AMP accumulation (TSH, 0.03-10 mU/ml) as well as the cyclic AMP-independent inositol trisphosphate (InsP3) generation (TSH, 1-10 mU/ml). In the same 14 experiments, TSAb (0.10-28 mg/ml) enhanced cyclic AMP intracellular levels as expected while they did not induce any InsP accumulation. Even when TSAb increased cyclic AMP levels to the same or higher values as those obtained with TSH concentrations allowing InsP3 generation, TSAb were still unable to activate the phosphatidylinositol-Ca2+ cascade. The patterns of the response curves of TSAb and TSH on cyclic AMP accumulation were different, suggesting that different mechanisms may be involved. In addition, unlike TSH, TSAb were not able to stimulate H202 generation, which in human tissue mainly depends on the activation of the phosphatidylinositol-Ca2+ cascade. Immunoglobulins from six additional Graves' patients lacking measurable cyclic AMP-stimulating activity in both slices and cells systems did not activate phospholipase C either. In conclusion, our results show that TSAb do not share all the metabolic actions ofTSH on human thyroid tissue. The data provide support for the concept that the pathogenesis of Graves' disease can be fully accounted for by the ability of TSAb to stimulate adenylate cyclase. This work also confirms that TSH activates the cyclic AMP and the phosphatidylinositol cascade by independent pathways in the human thyroid. (J. Clin. Invest. 1991. 87:1634-1642 
Introduction
Thyroid hyperfunction and growth in Graves' disease is ascribed to the thyrotropin (TSH)'-mimicking effect ofautoan- 1 . Abbreviations used in this paper: ASP, ammonium sulfate precipitates; InsP, inositol phosphates; KRB, Krebs-Ringer bicarbonate buffer; TSAb, thyroid-stimulating antibodies; TSH, thyrotropin. tibodies directed against the TSH receptor on the surface of thyroid cells (for a review see references 1 and 2). In human thyroid, we have previously shown that TSH could activate the two main pathways of cell regulation (3) : the cyclic AMP cascade in which activation of adenylate cyclase generates cyclic AMP, and the phosphatidylinositol cascade in which the receptor-activated phospholipase C releases two second messengers from phosphatidylinositol 4,5-bisphosphate: diacylglycerol and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3)-Ins (1, 4, 5) P3 itself activating Ca2' release from intracellular stores (4) . We have shown that InsP3 accumulation was cAMP-independent (3) . Several methods are currently used for the detection of TSAb, mainly based on adenylate cyclase stimulation, as measured in human thyroid slices, cells or membranes, or in FRTL5 cells (2) . Enhancement of cyclic AMP accumulation could certainly account for the known effect of TSAb on the human thyroid. Indeed, in dog and human thyroid, hormone secretion is stimulated by agents that increase cyclic AMP levels and inhibited by those that increase Ca2+ levels or activate protein kinase C (5) (6) (7) . Cyclic AMP mediates the TSH-induced thyroid cell differentiation and proliferation (8, 9) . However, claims have appeared for the existence of a growth-stimulating immunoglobulin (thyroid growth-stimulating antibodies or TGSAb), separate from TSAb, that might cause thyroid growth in Graves' disease and some euthyroid goiters through a pathway distinct from adenylate cyclase (10) (11) (12) (13) . These results were in contradiction with the findings ofZakarija et al. who showed a strict parallelism between growth and cyclic AMP accumulation-stimulating activities in Graves' immunoglobulins (14) . These in vitro studies on human thyroid slices were initiated to determine whether Graves' disease immunoglobulins reproduced one or both of the primary metabolic effects of TSH (adenylate cyclase and phospholipase C activation) that might be relevant to the increased function ofthe gland and essential for the development of thyrotoxicosis.
Methods
TSAb. Sera were obtained from 25 patients with hyperthyroidism due to Graves' disease (20 women, 5 men; age 17-58, mean 53). The diagnosis was based on the classical clinical findings ofthyrotoxicosis (with or without goiter or ophthalmopathy) associated with elevated T4, T3, and undetectable TSH levels, and a diffuse radioactive iodine uptake. Blood samples were obtained at the time when diagnosis was made in 16 patients while 9 of them were under methimazole therapy. The number of sera without measurable TSAb activity in both the Rapoport and the slices' assay systems was not different in the group of treated patients (4 of 16, 25%) than in the untreated group (2 of9, 22%). Serum was separated by centrifugation of 50 ml clotted blood. Control sera of healthy subjects were also used. Crude IgG was prepared by ammonium sulfate precipitation (15) . After precipitation and centrifugation, water was added to the pellet until complete dissolution and the IgG concentration was measured by its extinction coefficient at 280 nM. Samples were then dialyzed against NaCl free Hanks' medium for experiments on cells and against Krebs-Ringer bicarbonate (KRB) buffer for experiments on slices. Preparation of highly purified IgG on protein A sepharose columns was performed for two samples and provided no advantage in comparison with the ammonium sulfate precipitation technique. TSAb activities in the IgG fractions were checked in the Rapoport bioassay (15) . Briefly, monolayer cultures of human thyrocytes, which had been frozen in liquid N2 after primary culture and then thawed, were exposed to TSH or TSAb in hypotonic medium (NaCl free Hanks) for 4 h at 370C. Each assay contained TSH standards diluted in control IgG used at the same concentration as the TSAb samples. Cyclic AMP released into the medium was measured by RIA (15) .
Human thyroid tissue. For slices experiments, human thyroid tissue was obtained from euthyroid patients undergoing lobectomies for resection of solitary "cold" nodules. Only the healthy normal looking nonnodular tissue was used and cut into thin slices of 50 mg wet wt with a Stadie-Riggs microtome within 10-30 min of surgical resection. Slices were randomly assigned to inositol phosphates and cyclic AMP experiments. For cells in culture, thyroid tissue came from surgically treated Graves' patients.
Inositol phosphates measurements. Slices were incubated at 370C, under an atmosphere of0JCO2 (15:5, vol/vol) in 2 ml ofKRB, supplemented with 8 mM glucose, and 0.5 g/liter of bovine serum albumin. In the first 4-h preincubation, 20 ICi/ml 3H-inositol (sp act 16.5 Ci/ mmol) was added to this medium. Tissue was then transferred to fresh unlabeled incubation medium to which lithium was added after 15 min. After a further 5 min, slices were put for 1 h in a third series of flasks containing the tested agents (TSH, TSAb, control IgG) in the presence of 10 mM LiCl. Incubation was stopped by rapid immersion of the slices in (3%) ice-cold perchloric acid. After homogenization and centrifugation (2,000-g/l 0 min), the pellet was washed with 1 ml of 1% cold perchloric acid and recentrifuged. The combined supernatants were neutralized to pH 7.8 by the addition of 760 mM KOH in the presence of a 380-mM Hepes buffer. 3H-labeled inositol phosphates from the supernatants were eluted in a stepwise fashion through an anion exchange column of AG,-X8 resin (formate form, 100-200 mesh; Biorad, Watford, UK) (16) . Intracellular InsP3 is expressed as cpm/100 mg wet wt tissue. Incorporation of 3H-inositol into the total phosphatidylinositides pool was estimated after chloroform/methanol extraction of lipids from the pellet ( 17) .
Cyclic AMP measurements. Slices were incubated following the same protocol as for inositol phosphates measurements but without 3H-inositol. For the test incubation of 1 h, medium was supplemented with 100 gM Ro 20-1724 as a cyclic AMP-specific phosphodiesterase inhibitor. The slices were then dropped into boiling water for 5 min, homogenized, centrifuged, and the supernatant lyophilized. The tissue extracts were resuspended in water and cyclic AMP was measured in a binding assay using protein kinase from bovine skeletal muscle (18) . Intracellular cyclic AMP concentrations were expressed as pmol/100 mg wet wt tissue.
H202 determinations. Measurements were performed according to the method of Benard and Brault (19) based on the conversion of the nonfluorescent substrate homovanillic acid to a fluorescent derivative in the presence of H202 and peroxidase. Slices were preincubated for 1 h in KRB buffer supplemented with 8 mM glucose and 0.5 g/liter BSA, then transferred to fresh medium containing 0.1 mg/ml horse radish peroxidase type II, 440 ,M homovanillic acid and the agonist tested.
The fluorescence of the medium was measured 90 min later (20) .
Materials. TSH was used as Thytropar ( 
Results
Effects ofGraves' immunoglobulins on cyclic AMP accumulation. Among the 25 ammonium sulfate precipitates (ASP) tested, 6 were negative for cyclic AMP-stimulating activity in both the Rapoport and the slices system, while 19 ofthem were active in one or both of the assays. In the Rapoport bioassay (15), the potency ofthe TSAb were expressed as equivalents of mU TSH in the assay and ranged from 0.001-10 mU TSH ( Fig. 1 ). All ASP were then used for cyclic AMP determinations on human thyroid slices, in which their activities were also expressed as equivalents of mU TSH (range 0-3.3 mU TSH).
As expected from the lower sensitivity of the slices system, three sera showed cyclic AMP activities in the first assay without any activity in the second (No. [17] [18] [19] . One ASP (No. 14) had no detectable cyclic AMP-generating activity in the Rapoport bioassay, but it was positive in the slices system. For the 15 other ASP, there was a good correlation between the activities in both assays (r = 0.71, n = 15, P < .01). The activity ofTSAb preparations was largely independent of the origin of the human thyroid tissue used for the test. Indeed, 7 ASP used at constant concentrations had the same relative activity versus a standard TSH concentration action curve in two or three different thyroid tissues (data not shown). As observed earlier, there was no correlation between the extent of cyclic AMP enhancement and clinical parameters, such as goiter size, severity of hyperthyroidism, and/or ophthalmopathy (21) .
Comparison ofcyclic AMP and InsP3 generations induced by TSH and TSAb. 14 Figure 1 . Comparison of the strength of cyclic AMP-stimulating activities for Graves' sera No. 1-19 in the Rapoport bioassay (abscissa) and in our in vitro incubated slices system (ordinate). TSAb were used for maximal concentrations ranging from 0.1 to 28 mg/ml (as expressed in Fig. 2 ). Their potencies are expressed as equivalents of mU TSH (Equiv. mU TSH) and ranged from 0 to 10 for cells. For slices, some TSAb cyclic AMP-stimulating activities (5, 8) exceeded highest cyclic AMP stimulation levels obtained with TSH. Correlation coefficient, r = 0,71; P < 0.01. 10 mU/ml) significantly increased cyclic AMP accumulation and InsP3 generation, the latter at higher concentrations (TSH, 1-10 mU/ml). In the same experiments, TSAb (0.10-28 mg/ ml) also enhanced cyclic AMP levels but did not induce InsP3 accumulation. Dilutions of Graves' patients IgG did not reveal any InsP3 effect. When analysis ofthe data was restricted to the particular subset of TSAb, which increased cyclic AMP to the same values as those obtained using TSH concentrations allowing InsP3 generation (experiments 1-10, n = 10), no TSAb effect on the latter became evident. The same results were found for the inositol monophosphate and inositol bisphosphate fractions, while the total 3H-inositol content of the phospholipid pellet was not influenced by TSH or TSAb (data not shown).
In 7 experiments (2, 3, 4, 6, 11, 12, 13) , control IgG from healthy subjects induced a slight increase in InsP3 generation of the same magnitude as the TSAb in the same experiments. This effect was thus related to the thyroid sample studied and not to any differential characteristics of the normal and Graves' IgG. The lack of effect of TSAb on inositol phosphates generation was not related to a negative interaction of Graves' IgG with receptor activated phospholipase C, since TSH-induced InsP3 responses were not inhibited by Graves' sera (3 experiments using sera 9, 11, 14) . Fig. 3 shows the results for one of these experiments (serum No. 1 1) . Cases 4, 5, 8, 9, 10 , and 12 in Fig. 2 show more detailed TSAb and TSH concentration-response curves for cyclic AMP and InsP3 accumulations. In these experiments, the TSH-induced cyclic AMP generation curve was biphasic (i.e., decreas-ing cyclic AMP for the highest TSH concentrations), while that for TSAb showed a linear concentration dependence or a plateau phase.
Effects of TSAb in comparison with TSH on H202 generation. 8 of the most potent TSAb ASP (No. 1-8) were tested on slices in order to determine whether they could induce H202 production (Table I) . H202 values for TSAb-stimulated slices were not different from the control values, except for TSAb No. 6 which inhibited H202 generation. TSH 10 mU/ml induced a 12-fold increase of H202 generation.
Comparison of cAMP and InsP3 generations induced by thytropar, bovine or human purified TSH preparations. Fig. 4 shows that the biphasic effect of TSH on cAMP is produced by the commercial and purified bovine TSH preparation, as well as by purified human InaP3 (*103cpm/lOOmg w-w-t.) 10 -. (3) 20 5 (2) 19 6 (2) 12 7 (2) Effects ofGraves' immunoglobulins without TSAb activities on InsP3 generation. None ofthe 6 ASP lacking TSAb activities as defined in Methods was able to increase InsP3 accumulation in the slices (data not shown). Discussion % -18 -P."
As TSH activates both the cyclic AMP and the phosphatidyl-60±28 inositol-Ca2' cascades in human thyrocytes (3) , we addressed 57±27 the question as to whether TSAb, the antithyrotropin receptor 75±24 antibodies responsible for Graves' disease, also activate these 37±16 two pathways. As expected, the thyroid slices system is less 42±10 sensitive to TSH and TSAb than that using thawed cells in 20±15* hypotonic medium: some sera elicited a cyclic AMP accumula-20±152 tion in the latter but not in the former system. However, except 69±42 for a few sera (experiments 14, 17, 18, 19) , a good parallelism 72±37 was achieved between cyclic AMP responses to TSAb in both 847±106t systems (thawed cells and slices). Thus, the more physiological system, human thyroid slices incubated in vitro can be considyves' sera presented in Fig. ered as a good model to investigate TSAb activities as they are ressed as means±SD of usually detected and defined using the more sensitive Rapor of experiments in tripli-port bioassay. In contrast to the FRTL5 cell line and dog thyrocytes in primary culture, in the case of human thyrocytes, it has been demonstrated that TSH activates the PtdIns-Ca2+ cascade in the same range of concentrations eliciting other physiological effects (3) . These facts raise the possibility of a role for the PtdIns-Ca2+ cascade in TSAb action. IgG which bind to thyroid membranes are heterogenous and may contain activities which stimulate or inhibit adenylate cyclase (22, 23). Thus, depending on the titer and/or affinity of these two activities, the response in the TSAb assays could clearly vary with the relative concentrations of the IgG concerned (such variations have been demonstrated by Zakarija and McKenzie [22] ). Therefore, we considered it important to assay TSAb samples at different IgG concentrations since, at a single concentration, some may appear negative while positive at a higher or lower I | concentration. None of the concentrations ofthe various TSAb 10 mU TSH (Log) tested were able to elicit phospholipase C activation as measured by InsP3 generation. This lack of TSAb effect is not due to a blocking effect of the sera, as the TSH action on the InsP3 generation itself was not inhibited in the presence ofthese IgG.
These results show that at serum TSAb concentrations usually measured in vivo, no activation of the PtdIns-IP3 pathway is observed. Preliminary data obtained by B. Corvilain and E. Laurent show that H202 generation and protein iodination in human thyroid mainly depend on the activation of the I I WPtdIns-InsP3-Ca2+ cascade and are not stimulated by agents that increase cyclic AMP (24) . Our findings concerning the failure of TSAb to induce any H202 generation are thus not surprising. This suggests that activation of adenylate cyclase by TSAb also fully accounts for their effects on human thyroid cells. Such a conclusion fits in well with the fact that activation of the cyclic AMP cascade stimulates dog and human thyrocyte secretion, proliferation, and differentiation expression (8, 9) (as observed in Graves' disease), while activation of other cas-10 mU TSH (Log) cades, the phorbol ester-protein kinase C pathways, or the ion-response curves to growth factor protein-tyrosine kinase pathway, leads to proli-. ) and human puriferation and loss of differentiated expression and function ( ,---lj clear decrease of hormone action at high concentrations. This effect is not due to the presence of contaminants in the bovine TSH preparation used, since it was also observed when using purified bovine TSH (40 IU/mg) or purified human TSH (1 1 IU/mg). Such a biphasic effect was never observed with TSAb. These facts could explain that at high TSAb concentrations, cyclic AMP accumulations were sometimes higher than the maximal TSH effects (experiments 5 and 8 from Fig. 2 ). This second discrepancy further distinguishes TSAb and TSH actions. The decreased effect of TSH on cyclic AMP production was generally observed for hormone concentrations eliciting the InsP3 generation effect. It is therefore possible that the stimulation by TSH at a high concentration of the phosphatidyl inositol cascade itself could inhibit cyclic AMP generation. Such an effect could result from direct activation of the inhibitory GTP binding protein Ni (as for norepinephrine a, effects), from the inhibition of the activating GTP binding protein N5 by a protein kinase C induced phosphorylation or from Ca2`calmodulin activation of a cAMP phosphodiesterase.
The existence of IgG stimulating thyroid growth independently of cyclic AMP in the serum of some hyperthyroid or even euthyroid goitrous patients has been suggested (10, 1 1, 28). However, these results were sometimes based on inadequate methodologies (29, 30) and the experiments were never obtained with human thyroid cells or tissue. It has since been shown that cyclic AMP is the mediator of TSH mitogenic action in the FRTL5 cell line (31) and besides, that the growth promoting action ofGraves' sera parallel their action on cyclic AMP accumulation in these cells (14) .
In conclusion, our data demonstrate that at concentrations similar to in vivo conditions, Graves' IgG are unable to activate the PtdIns-Ca2+ pathway in normal human thyroid tissue.
Thus, TSAb do not share all the metabolic actions of TSH on normal human thyroid tissue incubated in vitro. If there were two distinct TSH receptors, one controlling phospholipase C and the other adenylate cyclase activation (such as is the case for many other hormones and neurotransmitters [32] [33] [34] [35] [36] ), TSAb would only activate the receptor coupled to adenylate cyclase. If there is only one TSH receptor controlling two independent pathways (such as is the case for some muscarinic receptors [37] ), TSAb action on this receptor would be incomplete. With the recent cloning of a human TSH receptor the tools now exist to distinguish between these hypotheses (38, 39) .
